Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Immix Biopharma, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +1 vs. Q1 2025
- Shares held
- 2.26M
- −656.2K (−22.5%) vs. Q1 2025
- Total value
- $4.68M
- −$219.9K (−4.5%) vs. Q1 2025
- New holders
- 5
- 5 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMMX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 109 | $579.6M |
| Q1 2026 | 77 | $246.6M |
| Q4 2025 | 67 | $127.5M |
| Q3 2025 | 31 | $5.78M |
| Q2 2025 | 23 | $4.68M |
| Q1 2025 | 22 | $4.90M |
| Q4 2024 | 23 | $6.32M |
| Q3 2024 | 25 | $6.10M |
| Q2 2024 | 31 | $8.77M |
| Q1 2024 | 35 | $15.7M |
| Q4 2023 | 28 | $5.32M |
| Q3 2023 | 16 | $1.39M |
| Q2 2023 | 18 | $1.75M |
| Q1 2023 | 12 | $729.8K |
| Q4 2022 | 18 | $1.01M |
| Q3 2022 | 12 | $406.0K |
| Q2 2022 | 7 | $475.0K |
| Q1 2022 | 8 | $352.0K |
| Q4 2021 | 11 | $5.47M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Immix Biopharma, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bleichroeder LP | 850,000 | $1.76M | 0.43% | 00.0% | Unchanged |
| Vanguard Group Inc | 698,537 | $1.45M | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 161,115 | $333.6K | 0.00% | +373+0.2% | Added |
| Morgan Stanley | 124,919 | $258.6K | 0.00% | +42,627+51.8% | Added |
| Northern Trust Corp | 93,888 | $194.3K | 0.00% | −1,374−1.4% | Reduced |
| Susquehanna International Group, LLP | 50,826 | $105.2K | 0.00% | −4,436−8.0% | Reduced |
| State Street Corp | 42,960 | $88.9K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 40,301 | $83.4K | 0.00% | +28,477+240.8% | Added |
| Private Advisor Group, LLC | 31,225 | $64.6K | 0.00% | 00.0% | Unchanged |
| Tocqueville Asset Management L.P. | 29,300 | $60.7K | 0.00% | 00.0% | Unchanged |
| Velan Capital Investment Management LP | 25,000 | $51.8K | 0.05% | +25,000 | New |
| Tritonpoint Wealth, LLC | 24,526 | $50.8K | 0.00% | +24,526 | New |
| Virtu Financial LLC | 17,846 | $37.0K | 0.00% | +17,846 | New |
| SBI Securities Co., Ltd. | 17,500 | $36.2K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 16,040 | $33.0K | 0.00% | −1,000−5.9% | Reduced |
| UBS Group AG | 13,972 | $28.9K | 0.00% | +3,851+38.0% | Added |
| Colony Group, LLC | 11,900 | $24.6K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 11,168 | $23.0K | 0.00% | +11,168 | New |
| Raymond James Financial Inc | 525 | $1.09K | 0.00% | +525 | New |
| Wells Fargo & Company | 330 | $683 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 139 | $288 | 0.00% | +19+15.8% | Added |
| Tower Research Capital LLC (TRC) | 131 | $271 | 0.00% | −340−72.2% | Reduced |
| Northwestern Mutual Wealth Management Co | 80 | $166 | 0.00% | 00.0% | Unchanged |
| Cable Car Capital LLC | 0 | $0 | 0.00% | −779,358−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,833−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −11,250−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −35−100.0% | Sold out |